VSTM Stock Draws Bullish Targets As Cancer Data Strengthens

Verastem Inc. stocks have been trading up by 10.13 percent after promising clinical trial news boosted investor optimism.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading VSTM

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways

Detailed RAMP 201 data show avutometinib plus defactinib beating conventional care in recurrent low‑grade serous ovarian cancer across KRAS‑mutant and wild‑type patients, including strong results in Japan.
Two‑year RAMP 201 follow‑up, now in Gynecologic Oncology, confirms durable efficacy and safety backing the FDA’s accelerated approval in KRAS‑mutated disease.
Quarterly revenue hit $25.1M from the AVMAPKI FAKZYNJA co‑pack, while Fast Track KRAS G12D drug VS‑7375 advances in pancreatic cancer and NSCLC.
B. Riley lifted its VSTM price target from $16 to $19 with a Buy rating, as the Street’s mean target sits at $14.67.
RBC Capital says VSTM’s share price still fails to reflect growth potential as the A+F franchise nears profitability and VS‑7375 shows promising clinical differentiation.

Live Update At 12:31:59 EDT: On Wednesday, October 14, 2026 Verastem Inc. stock [NASDAQ: VSTM] is trending up by 10.13%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

VSTM is trading like a biotech that’s moving from story to numbers. Over the past few weeks, the stock has mostly held between $7.50 and $8.50, with recent closes clustering around $8.00–$8.20. That tells traders the market is digesting good news rather than chasing a blow‑off spike.

Intraday on the latest session, VSTM swung from a pre‑market low near $7.09 up through the low $9s before settling back around $8.20. That kind of range is a day trader’s playground, but it also shows real tug‑of‑war between profit‑takers and fresh buyers.

On the fundamentals, Verastem reported $40.1M in quarterly revenue, with $25.1M tied to the AVMAPKI FAKZYNJA co‑pack. Gross margin is a hefty 86.4%, but the company is still running heavy losses, with an operating loss of about $32.7M and negative free cash flow of roughly $43.9M this quarter. VSTM holds $136.4M in cash and short‑term investments and a current ratio of 2.3, giving it room to fund operations.

More Breaking News

Valuation is rich on classic metrics: price‑to‑sales around 8.7 and price‑to‑book above 15. For traders, that means VSTM trades on data and headlines, not on earnings—news flow is the main driver.

Why Traders Are Watching VSTM Now

The core of the VSTM story is its avutometinib plus defactinib combo in recurrent low‑grade serous ovarian cancer. New RAMP 201 analyses show this regimen delivering clinically meaningful responses and significantly longer progression‑free survival versus conventional care. That’s across both KRAS‑mutant and KRAS wild‑type patients, and even includes a Japanese cohort. For traders, that’s not just “good science”; it screams potential label and market expansion.

VSTM already has FDA accelerated approval for KRAS‑mutated LGSOC, which is what’s driving AVMAPKI FAKZYNJA revenue. Two‑year follow‑up data from RAMP 201 show those responses are durable and the safety profile holds up. When a peer‑reviewed journal like Gynecologic Oncology publishes the dataset, it adds another layer of credibility. This is the shift traders look for—moving from hype to accepted standard of care in a niche indication.

On top of that, Verastem is advancing VS‑7375, a KRAS G12D inhibitor with FDA Fast Track in pancreatic cancer and NSCLC. That keeps a second potential value driver in the pipeline, beyond the A+F franchise that RBC Capital says is nearing profitability by year‑end.

Wall Street is clearly leaning bullish. B. Riley just raised its VSTM price target from $16 to $19 and kept a Buy, while the broader analyst pack also sits at Buy with a mean target of $14.67. Wolfe Research joined with an Outperform. More coverage usually means more eyes, more liquidity, and sharper moves when fresh data hit.

Conclusion

VSTM is trading at the intersection of real revenue and still‑high clinical risk. The AVMAPKI FAKZYNJA co‑pack is already bringing in $25.1M per quarter, yet the company still posts steep losses and negative cash flow. That’s normal in biotech, but it means VSTM’s chart will continue to react violently to every major data update or regulatory step.

For active traders, the setup is clear. The daily chart shows a steady grind from the mid‑$7s to low‑$8s, with intraday spikes into the $9 area on heavy news‑driven volume. That’s classic momentum behavior: sharp moves on catalysts, then consolidation as the market reassesses. Each new RAMP 201 read‑out, VS‑7375 data drop, or price‑target move adds fuel. As Tim Bohen, lead trainer with StocksToTrade says, “There’s a pattern in everything; you just have to stick around long enough to see it.” That mindset applies here: the recurring rhythm of catalyst‑driven spikes and consolidations can offer repeatable trading opportunities for those who track the setup closely.

Street research from RBC Capital, B. Riley, and Wolfe puts a fundamentally bullish frame around VSTM, but traders still need a plan. As Tim Sykes likes to say, “Always focus on the pattern and the catalyst, then cut losses quickly when the thesis cracks.” With VSTM, the catalysts are clear—LGSOC label expansion, Japanese and broader RAS/MAPK opportunities, and the KRAS G12D program.

This article is for educational and research purposes only. Use the data, study the chart, respect the volatility, and let the price action—not the story alone—drive your trading decisions in VSTM.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!